Somatostatin eye drops - BCN Peptides

Drug Profile

Somatostatin eye drops - BCN Peptides

Alternative Names: COLIRIOBCN070660; Somatostatin 0.1% eye drops

Latest Information Update: 07 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BCN Peptides
  • Class Antihaemorrhagics; Antineoplastics; Cyclic peptides; Pancreatic hormones; Pituitary hormone release inhibiting hormones
  • Mechanism of Action Corticotropin-releasing-hormone-Inhibitors; Growth hormone-releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Diabetic retinopathy

Most Recent Events

  • 06 Oct 2017 Initial efficacy and adverse events data from the phase II/III EUROCONDOR trial in Diabetic retinopathy presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top